Neurological disorders account for roughly 45% of rare diseases; and 85% of rare and ultra-rare disease trace back to a single gene defect. Given this, the potential for regenerative therapies to benefit patients with central nervous system-based disorders is vast.
But the task at hand for companies in the CNS cell and gene therapy space is formidable.





